Vaccinate against the resistance mutation before it takes over
Resistance often arrives as the same few mutations. Teaching the immune system to recognise them in advance could remove the escaping cells while they are still rare.
Recurrent resistance alleles such as EGFR T790M, ESR1 hotspot mutations and KRAS secondary mutations create novel peptides that may be presented on MHC. An off-the-shelf vaccine or T-cell product against a small set of public resistance neoantigens, given at the start of or during targeted therapy, would apply immune pressure precisely to the cells that are expanding under drug pressure.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- No one can predict who responds to immunotherapy · Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating.
Pages like this
not linked directly; found by shared links- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- CompanySerova
- CompanyGritstone bio
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonKellie N. Smith
- IdeaCut off the emergency programme cancer cells use to survive treatment
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- PersonYuquan Wei
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- IdeaA frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- PersonMalachi Griffith